Natera saw total Q4 2016 revenues decline to $49.3 million, despite an increase in testing volumes.
The GenomeWeb Index rose more than 6 percent in January, outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.
Going forward, Natera said it will market its Panorama NIPT assay and carrier screening test Horizon directly to physicians.
The investment bank set a price target of $18.00 for shares of the molecular diagnostics company.
The organization will promote public awareness of cfDNA-based NIPT, encourage legislation supporting testing, and push for reimbursement policy changes.
Natera alleges that Bio-Reference broke a contract by promoting a NIPS test based on Illumina technology over Panorama.
Natera will design a personalized liquid biopsy assay for each patient and will test its ability to monitor disease progression and treatment response.
The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.
The firm said it would use any net proceeds for R&D, working capital, and to potentially acquire other technologies or businesses.
Natera has focused on tapping into the average risk market for its suite of noninvasive prenatal assays, which it said is paying off.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.